"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial of vandetanib alongside MIBG radio-targeted therapy for advanced phaeochromocytomas and paragangliomas (VIBRaNT)
This trial looked at a drug called vandetanib alongside MIBG radio-targeted therapy for a rare type of neuroendocrine tumour. The trial was supported by Cancer Research UK.
More about this trial
A phaeochromocytoma (pronounced (fey-oh-cromo-sy-toma) is a rare cancer that starts in the inner part of the adrenal gland (the adrenal medulla). The
Paragangliomas are another rare type of neuroendocrine tumour. They are similar to phaeochromocytomas, but start in other parts of the body.
If a phaeochromocytoma can’t be removed with surgery, or has spread to another part of the body, doctors use a treatment called MIBG radio-targeted therapy.
MIBG is a chemical that is usually taken up by phaeochromocytoma cells. If you have this treatment, the MIBG is attached to a radioactive form of iodine. You have this as an injection into a vein and it circulates in your bloodstream. It is taken up by the cancer cells wherever they are in your body, and the radioactive iodine kills them.
Researchers are looking for ways to improve treatment. In this trial, they wanted to test a drug called vandetanib. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
The aim of the trial was to find the best dose of vandetanib to have alongside MIBG radio-targeted therapy for phaeochromocytomas and paragangliomas that can’t be completely removed with surgery.
Summary of results
This trial was never finished so there are no results available. The researchers were unable to recruit any patients.
How to join a clinical trial
Dr Christina Thirlwell
Dr Debashis Sarker
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUKD/13/003.